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Impact of Treatment with Human Immunodeficiency Virus (HIV) Protease
Inhibitors on Hepatitis C Viremia in Patients Coinfected with HIV
O. T. Rutschmann, F. Negro, B. Hirschel, A. Hadengue, Division of Infectious Diseases and of Gastroenterology, and Laboratory
of Virology, University Hospital, Geneva, SwitzerlandD. Anwar, and L. H. Perrin
The impact of human immunodeficiency virus (HIV) protease inhibitors on hepatitis C (HCV)
viremia was assessed in 19 patients infected with both HIV and HCV. HIV and HCV RNA levels
were measured before and during treatment with protease inhibitors. Before treatment, mean levels
of HCV RNA were 5.3 log for HCV RNA and 5.0 log for HIV RNA. CD4 lymphocyte counts were
63/mm3. After 6 weeks of treatment, a mean reduction of 2.1 log10 in HIV RNA (P  .001) and a
mean ({SE) increase of 73 ({21) CD4 and 296 ({70) CD8 cells were observed (P .05). In contrast,
both HCV viremia (/0.4 log { 0.1) and alanine aminotransferase increased (P  .04). HCV RNA
levels returned to baseline after 17 and 32 weeks of treatment. Thus, potent anti-HIV regimens with
protease inhibitors may temporarily worsen HCV status despite improvement of HIV parameters.
therapy, after 6 weeks of treatment, and every 3 to 4 monthsUntil recently, the prognosis of persons infected with the
thereafter.human immunodeficiency virus (HIV) was poor. New combi-
Immunologic and virologic parameters. CD4 and CD8 cellnations of antiretroviral agents, including protease inhibitors,
counts and HIV-1 RNA levels were determined at each clinicalhave resulted in decreased HIV RNA levels, increased CD4
evaluation using the HIV-1 Amplicor monitor test with a lowercell counts, and fewer new opportunistic infections, resulting
detection limit of 200 HIV RNA copies/mm3.
in prolonged survival [1].
HCV viremia. Plasma samples were processed immediately
Coinfection with hepatitis C virus (HCV) and HIV is fre- after sampling at the time of HIV-1 RNA determination and kept
quent in injecting drug users and in transfused hemophiliacs frozen at 0757C. HCV was measured quantitatively in batches at
[2]. If these persons survive longer because of better antiret- the end of the study (HCV Amplicor monitor test; Roche).
roviral treatment, they may yet succumb to chronic liver disease Liver enzymes. Levels of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) were measured at each clinicalcaused by HCV. Treatments with HIV protease inhibitors may
evaluation.help to control HCV infection by improving immunity; in addi-
Statistical analyses. Baseline values were compared with on-tion, HIV protease inhibitors might interact with the recently
treatment values using Wilcoxon signed rank test (SPSS for Win-identified HCV protease [3]. However, the impact of therapeu-
dows, version 5.0.1; SPSS, Chicago).tic regimens containing HIV protease inhibitors on HCV infec-
tion is unknown. It was the aim of this trial to analyze changes
in HCV viremia in HIV-infected persons treated with HIV Results
protease inhibitors.
Patient characteristics. Nineteen HIV-1– and HCV-sero-
positive patients (16 males, 3 females) were evaluated. Modes
Patients and Methods of transmission of HIV infection were intravenous drug use
(16), transfusion (2), and sexual contact (1). Three patients had
Patients. Patients coinfected with HCV and HIV-1 were in-
not received any antiretroviral agent. Sixteen patients had been
cluded if they had detectable HCV viremia in plasma (Amplicor
pretreated for a mean of 143 weeks with one to five antiretrovi-monitor kit; Roche, Basel, Switzerland) and indications for initiat-
ral agents, including zidovudine (14), didanosine (11), zalcita-ing HIV protease inhibitor therapy. They were prospectively fol-
bine (4), lamivudine (3), stavudine (8), and saquinavir (4).lowed at the outpatient AIDS clinic of the University Hospital of
Antiretroviral treatments. The choice of protease inhibitorGeneva from May 1996 to April 1997, with clinical evaluation
and blood sampling before the initiation of the protease inhibitor therapy was determined by then-current guidelines [4], previ-
ous antiretroviral treatments, and potential interactions with
concomitant medications. Nine patients were treated with rito-
navir (600 mg, twice daily), 7 with indinavir (800 mg, three
Received 7 July 1997; revised 1 October 1997. times per day), and 3 with a combination of saquinavir (600
Presented in part: 37th Interscience Conference on Antimicrobial Agents mg, twice daily) and ritonavir (600 mg, twice daily). Seventeenand Chemotherapy, Toronto, Canada, September 1997 (abstract I-165).
patients received reverse transcriptase inhibitors, including zi-Reprints or correspondence: Dr. Olivier T Rutschmann, Division of
Infectious Diseases, University Hospital, 1211 Geneva 14, Switzerland dovudine, lamivudine, or stavudine in combination with prote-
(Rutschma@dminov1.hcuge.ch). ase inhibitors.
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Table 1. Evolution of HCV RNA, HIV RNA, CD4 and CD8 cell counts, and alanine (ALT) and aspartate (AST) aminotransferase levels in
19 HIV-1–infected patients treated with HIV protease inhibitors.
P*
Changes at
Parameter, Baseline Week 6 vs. Week 32 vs. Week 32 vs.
mean { SE value Week 6 Week 17 Week 32 baseline baseline week 6
No. of patients 19 19 18 17
Log HCV RNA
(copies/mL) 5.27 { 0.22 /0.37 { 0.13 00.16 { 0.23 00.14 { 0.19 .01 .83 .02
ALT (IU/L) 57 { 9 /17 { 10 /23 { 20 /19 { 11 .04 .10 .72
AST (IU/L) 64 { 9 /4 { 9 /16 { 20 05 { 7 .42 .38 .55
Log HIV RNA
(copies/mL) 4.99 { 0.14 02.07 { 0.11 02.44 { 0.19 02.56 { 0.19 .001 .001 .04
CD4 cells/mm3 63 { 13 /73 { 21 /89 { 18 /114 { 28 .002 .001 .02
CD8 cells/mm3 456 { 68 /296 { 70 /244 { 63 /197 { 85 .001 .03 .12
* Wilcoxon matched paired test.
({0.14) log, and CD4 and CD8 cell counts were 63 ({13) and Discussion
456 ({68) cells/mm3, respectively. Mean ALT and AST values In this group of patients with advanced HIV infection (mean
were 57 ({9) and 64 ({9) IU/L, respectively. CD4 cell counts of 63/mm3 at inclusion), with the majority (16/19)
Evolution of HCV viremia. Six weeks after initiation of having been heavily pretreated, HIV protease inhibitors produced a
treatment with HIV protease inhibitor, a statistically significant major decrease in HIV RNA and an increase in CD4 and CD8
mean ({SE) increase of 0.37 ({0.13) log was observed cell counts. Unexpectedly, the improvement in HIV virologic and
immunologic parameters was initially associated with a significant(P  .01; table 1). Thus, 9 patients showed an increase ⁄0.5
increase in HCV RNA. HCV RNA levels remained stable overlog, and 10 had a positive or negative variation 0.5 log in
various time intervals in patients with chronic HCV infection whoHCV RNA. After 4 months of treatment, HCV viremia returned
did not receive anti-HCV therapy [5]; thus, the initial increaseto values slightly but not significantly (P  .9) below baseline
observed in our patients was unexpected and most probably duewith a mean decrease of 0.2 log ({0.2). After 8 months of
to the recent modification of anti-HIV therapy.
treatment, HCV RNA values stabilized just below baseline, Increase in HCV viremia was initially associated with a signifi-
with a decrease of 0.1 ({0.2) log compared with baseline (P cant increase in ALT levels. Although our data cannot rule out a .8). This pattern was observed in patients treated with indi- hepatotoxic effect of HIV protease inhibitors, they contrast with
navir or ritonavir, but the highest increases were observed in 2 previously reported hepatic toxicity of protease inhibitors, which
patients treated with a combination of ritonavir plus saquinavir was only sporadic and usually included increases in both ALT and
AST [6]. In contrast, an increase in ALT levels was also observed(increase in HCV RNA of 1.13 and 1.50 log, respectively, after
in HCV-infected patients who relapsed after treatment with inter-6 weeks of treatment).
feron-a [7]. In these patients, elevation of ALT level was oftenEvolution of HIV viremia. A persistent decrease of HIV
preceded by an increase in HCV viremia and followed by a riseRNA was observed (mean { SE): 02.1 ({0.1) log, 02.4
of the IgM anti-core antibody [7]. For the practicing physician, it
({0.2) log, and 02.6 ({0.2) log after 6 weeks and 4 and 8
is important to recognize this phenomenon, so the ALT increase
months, respectively (P  .001; table 1). in not attributed to drug toxicity, which might lead to erroneous
Evolution of CD4 and CD8 cell counts. An increase in interruption of treatment with protease inhibitors.
CD4 cells was observed over time (mean { SE): /73 cells The initial increase in HCV RNA during the first weeks of an
({21) after 6 weeks of treatment, /89 cells ({18) after 4 effective anti-HIV treatment may be linked to two pathophysio-
logic mechanisms. First, we observed a steep and rapid increasemonths, and /113 cells ({28) after 8 months of treatment
in CD8 cell counts, which was maximal during the first weeks of(P  .002). The increase in CD8 cell counts was highest after
treatment with protease inhibitors in 16 of 19 patients. T cell6 weeks of treatment but persisted during the follow-up period:
response is crucial for the control of a number of viral infections,/296 cells ({70) at week 6, /224 cells ({63) and /197 cells
especially HCV [8]. Thus, an increase in the concentration of({85) at months 4 and 8, respectively (P  .03; table 1).
cytotoxic T lymphocytes might cause an immune-mediated lysis
Evolution of AST and ALT. No significant changes were of HCV-infected cells, resulting in a release of HCV and increase
observed in AST values over time (table 1). A statistically in ALT level.
significant increase (17 IU/L { 10) in ALT values was noticed Second, endogenous interferon is known to play an important
at week 6. ALT values after 4 and 8 months of treatment were role in the control of HCV replication [9–11]. Cribier et al. [11]
showed that high levels of HIV viremia were associated with highnot statistically significantly different from baseline values.
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ficiency virus infection and CD4 cell counts of 200 per cubic millimeterinterferon-a levels in patients coinfected with HCV and HIV.
or less. N Engl J Med 1997;337:725–33.Thus, decreased HIV RNA levels could be associated with reduc-
2. Chamot E, de Saussure P, Hirschel B, De´glon JJ, Perrin LH. Incidence oftion in endogenous interferon-a, leading to a transient increase in
hepatitis C, hepatitis B and HIV infection among drug users in a metha-HCV viremia.
done-maintenance programme. AIDS 1992;6:430–1.
Over the following months, low HIV RNA levels were main- 3. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis
tained and CD4 cell counts continued to increase. This was associ- C virus NS3 protease domain complexed with a synthetic NS4A cofactor
ated with a return and stabilization of HCV viremia to values peptide. Cell 1996;87:343–55.
slightly below baseline. There is no agreement on the relation 4. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for
HIV infection in 1996—recommendations of an international panel.between CD4 cell counts and levels of HCV. In some studies,
JAMA 1996;276:146–54.HCV viremia was not linked to the degree of immunosuppression
5. Yoshimura E, Hayashi J, Ueno K. No significant changes in levels ofinduced by HIV [12, 13], whereas others clearly demonstrated an
hepatitis C virus (HCV) RNA by competitive polymerase chain reactionincrease in HCV viremia associated with progression of immuno-
in blood samples form patients with chronic HCV infection. Dig Dis
suppression [14, 15]. In our patients, the pattern of HCV RNA
Sci 1997;42:772–7.
levels during the second phase of treatment suggests that the con- 6. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of
stant and persistent increase in CD4 cell counts contributed to the ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N
stabilization of HCV viremia despite the initial increase. Engl J Med 1995;333:1534–9.
7. Negro F, Abate ML, Mondardini A, et al. The fluctuations of hepatitis CIn conclusion, in this group of HCV- and HIV-infected patients
virus RNA and IgM anti-HCV (core) serum levels correlate with thosewith advanced immunosuppression, effective anti-HIV treatments
of alanine aminotransferases during the hepatitis relapses of patientsresulted in an initial increase in HCV viremia that then returned
treated with interferon. J Viral Hepat 1995;2:171–4.to baseline values. This suggests that improvement in HIV status
8. Battegay M. Immunity to hepatitis C virus: a further piece of the puzzle.
may temporarily worsen HCV status, either by an increased de-
Hepatology 1996;24:961–3.
struction of hepatocytes through cytotoxic T cells or decreased 9. Greenway AL, Hertzog PJ, Devenish RJ, Dudley FJ, McMullen GL, Lin-
endogenous interferon. This also emphasizes that HIV protease nane AW. Immunolocalisation of interferon-alpha in hepatitis C patients
inhibitors have certainly no direct anti-HCV activity and that im- and its correlation with response to interferon-alpha therapy. J Hepatol
1994;21:842–52.provement of immunologic parameters is not sufficient to control
10. Pirisi M, Fabris C, Toniutto P, et al. Endogenous interferon-a concentra-HCV infection. Further studies are warranted to better explore the
tion and outcome of interferon treatment in patients with chronic hepati-relationship between restoration of immune function and HCV
tis C. Dig Dis Sci 1997;42:767–71.infection, and major efforts are required to develop specific anti-
11. Cribier B, Schmitt C, Rey D, Lang JM, Kirn A, Stoll-Keller F. Role
HCV protease inhibitors.
of endogenous interferon in hepatitis C virus (HCV) infection and in
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